Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms LUX-Bladder 1
- Sponsors Boehringer Ingelheim
- 14 Feb 2017 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
- 14 Feb 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Feb 2019.
- 11 Jul 2016 Status changed from not yet recruiting to recruiting.